Return on Capital Employed Overview: Accelerate Diagnostics

After pulling data from Benzinga Pro it seems like during Q2, Accelerate Diagnostics AXDX posted sales of $2.80 million. Earnings were up 12.17%, but Accelerate Diagnostics still reported an overall loss of $17.59 million. In Q1, Accelerate Diagnostics brought in $2.52 million in sales but lost $20.03 million in earnings.

What Is ROCE?

Changes in earnings and sales indicate shifts in Accelerate Diagnostics's Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q2, Accelerate Diagnostics posted an ROCE of 0.25%.

It is important to keep in mind ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but several factors could affect earnings and sales in the near future.

Return on Capital Employed is an important measurement of efficiency and a useful tool when comparing companies that operate in the same industry. A relatively high ROCE indicates a company may be generating profits that can be reinvested into more capital, leading to higher returns and growing EPS for shareholders.

In Accelerate Diagnostics's case, the positive ROCE ratio will be something investors pay attention to before making long-term financial decisions.

Analyst Predictions

Accelerate Diagnostics reported Q2 earnings per share at $-0.36/share, which did not meet analyst predictions of $-0.33/share.